

Parvo virus

Structure of Parvovirus

- Very small, non enveloped virus with single- stranded DNA genome.
- The genome is negative strand DNA, but there is no virion polymerase.
- The capsid with icosahedral symmetry.
- There is one serotype.

Receptors

The virus is highly tropic for **human erythroid cells**. The cellular receptor for B19 is **blood group P antigen (globoside)**.

P antigen is expressed on mature erythrocytes, erythroid progenitors, megakaryocytes, endothelial cells, placenta, and fetal liver and heart, which helps explain the narrow tissue tropism of B19 virus.

B19 virus replicate **only** when a cell is in the S phase , which explains why the virus replicates in red blood cells precursors but not in mature RBC

The replicative cycle of human B19 parvovirus

- After adsorption to host cell receptors, the virus penetrates and moves to the nucleus, where replication occurs.
- Cellular DNA polymerase is used by the virus single stranded DNA genome to provide the progeny genomes
- The viral mRNA is synthesized by cellular RNA polymerase from double strand intermediate.
- The progeny virions are assembled in the nucleus.

Transmission and epidemiology

- Respiratory route
 - Transplacental
 - Blood transfusion.
-
- B19 virus infection occurs world wide
 - Human are natural reservoir.

Pathogenesis and immunity

B19 virus infects primarily two types of cells:

- Red blood cell precursor (erythroblast) in the bone marrow which accounts for aplastic anaemia
- Endothelial cells in the blood vessels, which accounts in part for the rash associated with erythema infectiosum.

- Immunocomplexes composed of virus and IgM or IgG also contribute to the pathogenesis of the **rash and to the arthritis** that is seen in some adult patient.
- **Hydropes fetalis** is secondary to congestive heart failure caused by severe anemia due to death of B19 parvo virus infected erythroblast in the fetus.

Clinical findings

There are **five** important clinical presentations

Erythema infectiosum (Slapped Cheek Syndrome, Fifth Disease)

- Mild disease of childhood
- Characterized by bright red rash that is most prominent on the cheeks, accompanied by low grade fever, runny nose (coryza) and sore throat.
- A lacy , less intense erythematous rash appears on the body.
- The symptoms resolve in about 1 week.

- It is also called fifth disease. The four other macular rash of childhood are measles, rubella, scarlet fever and roseola

Diseases caused by Parvoviruse B19

- Erythema infectiosum ("fifth disease").
- polyarthralgia-arthritis syndrome in normal adults.
- aplastic crisis in patients with hemolytic disorders
- fetal infections including hydrops fetalis.



Aplastic crises

- Children with chronic anemia , such as sickle cell anaemia, thalassemia can have transient but severe aplastic anaemia (aplastic crises) when infected with B19 virus.
- People with normal RBC **don't** have clinically apparent anemia, although their RBC precursors are infected.

Fetal infections

- Infection during first and second trimester of pregnancy, the virus may cross the placenta and infect the fetus.
- First trimester associated with fetal death.
- Second trimester leads to hydrops fetalis.
- Third trimester do not results in important clinical finding.

Arthritis

- Parvo B19 virus infection in **adults** especially women, can cause arthritis mainly involving the small joints of the hands and feet bilaterally.
- It resembles rheumatoid arthritis.

Chronic B19 infection

- Immunodeficient patient especially HIV, chemotherapy or transplant patients can have **chronic anemia, leukopenia or thrombocytopenia** as a result of B19 infection

Laboratory diagnosis

- Fifth disease and aplastic crises are usually diagnosed by detection of IgM antibodies.
- B19 can be isolated from throat swab but this usually not done.
- In Immunocompromised patients antibodies may not be detectable, therefore, viral DNA in the blood can be assayed by PCR
- Fetal infection can be determined by PCR analysis of amniotic fluid.

Treatment

- No specific treatment
- Pooled Immunoglobulin may have beneficial effect on chronic infection in Immunocompromised patients.
- No vaccine or chemoprophylaxis is available.

